Nature Medicine, Published online: 10 June 2026; doi:10.1038/s41591-026-04436-0
Phase 1 results reveal that BBM-P002, a dual-target gene therapy co-delivering TH and DDC, is safe and well tolerated in Parkinson’s disease, with 12-month motor improvements signaling therapeutic potential.